These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 33474645)

  • 1. Effects of the Once-Weekly DPP4 Inhibitor Omarigliptin on Glycemic Control in Patients with Type 2 Diabetes Mellitus on Maintenance Hemodialysis: A 24-Week Open-Label, Multicenter Randomized Controlled Study.
    Yoshizawa Y; Hosojima M; Kabasawa H; Tanabe N; Ugamura D; Koda Y; Shimada H; Takasawa T; Ito T; Kitamura T; Kobayashi M; Suzuki Y; Narita I; Saito A
    Diabetes Ther; 2021 Mar; 12(3):655-667. PubMed ID: 33474645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized clinical trial evaluating the efficacy and safety of the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy.
    Shankar RR; Inzucchi SE; Scarabello V; Gantz I; Kaufman KD; Lai E; Ceesay P; Suryawanshi S; Engel SS
    Curr Med Res Opin; 2017 Oct; 33(10):1853-1860. PubMed ID: 28547998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, double-blind, non-inferiority trial evaluating the efficacy and safety of omarigliptin, a once-weekly DPP-4 inhibitor, or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy.
    Handelsman Y; Lauring B; Gantz I; Iredale C; O'Neill EA; Wei Z; Suryawanshi S; Kaufman KD; Engel SS; Lai E
    Curr Med Res Opin; 2017 Oct; 33(10):1861-1868. PubMed ID: 28548024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Omarigliptin, a Novel Once-Weekly Dipeptidyl Peptidase-4 Inhibitor, in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.
    Kamrul-Hasan ABM; Alam MS; Talukder SK; Dutta D; Selim S
    Endocrinol Metab (Seoul); 2024 Feb; 39(1):109-126. PubMed ID: 38417828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of omarigliptin, once-weekly dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes.
    Kawasaki E; Nakano Y; Fukuyama T; Uchida A; Sagara Y; Tamai H; Tojikubo M; Hiromatsu Y; Koga N
    World J Diabetes; 2021 Dec; 12(12):2087-2095. PubMed ID: 35047122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Efficacy of Omarigliptin (MK-3102), a Novel Once-Weekly DPP-4 Inhibitor for the Treatment of Patients With Type 2 Diabetes.
    Sheu WH; Gantz I; Chen M; Suryawanshi S; Mirza A; Goldstein BJ; Kaufman KD; Engel SS
    Diabetes Care; 2015 Nov; 38(11):2106-14. PubMed ID: 26310692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Randomized, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Adding Omarigliptin to Antihyperglycemic Therapies in Japanese Patients with Type 2 Diabetes and Inadequate Glycemic Control.
    Gantz I; Okamoto T; Ito Y; Sato A; Okuyama K; O'Neill EA; Engel SS; Lai E;
    Diabetes Ther; 2017 Aug; 8(4):793-810. PubMed ID: 28589493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Linagliptin monotherapy compared with voglibose monotherapy in patients with type 2 diabetes undergoing hemodialysis: a 12-week randomized trial.
    Mori K; Emoto M; Shoji T; Inaba M
    BMJ Open Diabetes Res Care; 2016; 4(1):e000265. PubMed ID: 27547421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment Burden on Once-Weekly Omarigliptin Versus Daily Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes: Randomized Controlled Trial (ONWARD-DPP4 Study).
    Ishii H; Kamei N; Shimono D; Niiya T; Tosaki T; Kitazawa T; Suzuki D; Wakasa Y; Seino H; Oishi M; Ohashi H; Higami K; Akai H;
    Diabetes Ther; 2023 Oct; 14(10):1639-1658. PubMed ID: 37468684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Omarigliptin for the treatment of type 2 diabetes.
    Tan X
    Endocrine; 2016 Oct; 54(1):24-31. PubMed ID: 27372109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension.
    Barnett AH; Patel S; Harper R; Toorawa R; Thiemann S; von Eynatten M; Woerle HJ
    Diabetes Obes Metab; 2012 Dec; 14(12):1145-54. PubMed ID: 22974280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of omarigliptin on glucose variability and oxidative stress in type 2 diabetes patients: A prospective study.
    Ohara M; Nagaike H; Fujikawa T; Kohata Y; Ogawa M; Omachi T; Sasajima R; Chiba H; Ara T; Sugawara A; Hiromura M; Terasaki M; Mori Y; Fukui T; Hirano T; Yokoyama H; Yamagishi SI
    Diabetes Res Clin Pract; 2021 Sep; 179():108999. PubMed ID: 34390762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Omarigliptin decreases inflammation and insulin resistance in a pleiotropic manner in patients with type 2 diabetes.
    Hattori S
    Diabetol Metab Syndr; 2020; 12():24. PubMed ID: 32211075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of dipeptidyl peptidase-4 inhibitor linagliptin in patients with type 2 diabetes undergoing hemodialysis.
    Terawaki Y; Nomiyama T; Takahashi H; Tsutsumi Y; Murase K; Nagaishi R; Tanabe M; Kudo T; Kobayashi K; Yasuno T; Nakashima H; Yanase T
    Diabetol Metab Syndr; 2015; 7():44. PubMed ID: 25995772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic-pharmacodynamic (dipeptidyl peptidase-4 inhibition) model to support dose rationale in diabetes patients, including those with renal impairment, for once-weekly administered omarigliptin.
    Jain L; Chain ASY; Tatosian DA; Hing J; Passarell JA; Kauh EA; Lai E
    Br J Clin Pharmacol; 2019 Dec; 85(12):2759-2771. PubMed ID: 31454094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Tolerability of Linagliptin in Patients With Type 2 Diabetes: A Comprehensive Pooled Analysis of 22 Placebo-controlled Studies.
    Lehrke M; Marx N; Patel S; Seck T; Crowe S; Cheng K; von Eynatten M; Johansen OE
    Clin Ther; 2014 Aug; 36(8):1130-46. PubMed ID: 25015594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Omarigliptin for the treatment of type 2 diabetes mellitus.
    Evans PM; Bain SC
    Expert Opin Pharmacother; 2016 Oct; 17(14):1947-52. PubMed ID: 27466703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized, double-blind, placebo-controlled dose-finding study of the dipeptidyl peptidase-4 inhibitor linagliptin in pediatric patients with type 2 diabetes.
    Tamborlane WV; Laffel LM; Weill J; Gordat M; Neubacher D; Retlich S; Hettema W; Hoesl CE; Kaspers S; Marquard J
    Pediatr Diabetes; 2018 Jun; 19(4):640-648. PubMed ID: 29171139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of vildagliptin, sitagliptin, and linagliptin as add-on therapy in Chinese patients with T2DM inadequately controlled with dual combination of insulin and traditional oral hypoglycemic agent.
    Tang YZ; Wang G; Jiang ZH; Yan TT; Chen YJ; Yang M; Meng LL; Zhu YJ; Li CG; Li Z; Yu P; Ni CL
    Diabetol Metab Syndr; 2015; 7():91. PubMed ID: 26500706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of linagliptin monotherapy compared with voglibose on postprandial blood glucose responses in Japanese patients with type 2 diabetes: Linagliptin Study of Effects on Postprandial blood glucose (L-STEP).
    Fujitani Y; Fujimoto S; Takahashi K; Satoh H; Hirose T; Hiyoshi T; Ai M; Okada Y; Gosho M; Mita T; Watada H
    Diabetes Res Clin Pract; 2016 Nov; 121():146-156. PubMed ID: 27710821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.